Developing Congestive Heart Failure CDISC Clinical Data Standards for Clinical Research and Drug Development.
制定用于临床研究和药物开发的充血性心力衰竭 CDISC 临床数据标准。
基本信息
- 批准号:9899106
- 负责人:
- 金额:$ 9.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-01 至 2020-11-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Project Summary/Abstract
CDISC has developed foundational standards over the last twenty years and published thirty-five
Therapeutic Area (TA) standards and updates for the past five years in collaboration with FDA-
CDER, in addition eleven TA standards are currently in development through a community-driven,
consensus-based process in collaboration with CFAST organizations and the CDISC global
community of reviewers. The objectives of this project are to build on existing CDISC clinical
data standards to develop congestive heart failure standards that span collection (CDASH),
organization (SDTM), analysis (ADaM), controlled terminology, as well as develop a number of
relevant Questionnaires, Ratings or Scales (QRS), using established CDISC processes and
CDISC SHARE tools. CDISC will engage CFAST stakeholders as well as the CDISC global
community in the development of these new congestive heart failure standards. The new
congestive heart failure standards will bring clarity to data and support FDA in reviewing many
different studies and allowing them to ‘speak the same language’.
项目摘要/摘要
CDISC在过去的20年里制定了基础标准,并发布了35项标准
过去五年与FDA合作的治疗区(TA)标准和更新-
CDER,此外,目前有11个TA标准正在通过社区驱动的、
与CFAST组织和CDISC全球合作的基于协商一致的进程
评论者社区。该项目的目标是在现有CDISC临床的基础上
数据标准,以开发跨越收集的充血性心力衰竭标准(CDASH),
组织(SDTM)、分析(ADAM)、受控术语以及制定许多
相关问卷、评级或量表(QR),使用既定的CDISC流程和
CDISC共享工具。CDISC将与CFAST利益相关者以及CDISC全球
社区正在制定这些新的充血性心力衰竭标准。新的
充血性心力衰竭标准将使数据更加清晰,并支持FDA审查许多
不同的研究,让他们“说同一种语言”。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sam HUME其他文献
Sam HUME的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sam HUME', 18)}}的其他基金
Leveraging CDISC innovative approaches and emerging technology to expedite development of open, end-to-end tobacco standards to facilitate regulatory submission, review and decision making.
利用 CDISC 创新方法和新兴技术加快开放、端到端烟草标准的制定,以促进监管提交、审查和决策。
- 批准号:
10907172 - 财政年份:2021
- 资助金额:
$ 9.96万 - 项目类别:
Leveraging CDISC innovative approaches and emerging technology to expedite development of open, end-to-end tobacco standards to facilitate regulatory submission, review and decision making.
利用 CDISC 创新方法和新兴技术加快开放、端到端烟草标准的制定,以促进监管提交、审查和决策。
- 批准号:
10413694 - 财政年份:2021
- 资助金额:
$ 9.96万 - 项目类别:
Leveraging CDISC innovative approaches and emerging technology to expedite development of open, end-to-end tobacco standards to facilitate regulatory submission, review and decision making.
利用 CDISC 创新方法和新兴技术加快开放、端到端烟草标准的制定,以促进监管提交、审查和决策。
- 批准号:
10524770 - 财政年份:2021
- 资助金额:
$ 9.96万 - 项目类别:
Developing Psoriasis CDISC Clinical Data Standards for Clinical Research and Drug Development.
制定用于临床研究和药物开发的银屑病 CDISC 临床数据标准。
- 批准号:
9899108 - 财政年份:2018
- 资助金额:
$ 9.96万 - 项目类别:
Developing Acute Kidney Injury CDISC Clinical Data Standards for Clinical Research and Drug Development.
制定用于临床研究和药物开发的急性肾损伤 CDISC 临床数据标准。
- 批准号:
9899104 - 财政年份:2018
- 资助金额:
$ 9.96万 - 项目类别:
相似海外基金
Wearable devices for reducing congestive heart failure hospitalizations
可减少充血性心力衰竭住院次数的可穿戴设备
- 批准号:
568003-2022 - 财政年份:2022
- 资助金额:
$ 9.96万 - 项目类别:
Postdoctoral Fellowships
Remote ischemic preconditioning for renal and cardiac protection in congestive heart failure (RICH) trial
充血性心力衰竭 (RICH) 试验中远程缺血预处理对肾脏和心脏的保护
- 批准号:
10426064 - 财政年份:2021
- 资助金额:
$ 9.96万 - 项目类别:
Novel target mechanism (renal nerves) for the beneficial actions of SGLT2 inhibition in congestive heart failure
SGLT2 抑制对充血性心力衰竭有益作用的新靶点机制(肾神经)
- 批准号:
10669642 - 财政年份:2021
- 资助金额:
$ 9.96万 - 项目类别:
Novel target mechanism (renal nerves) for the beneficial actions of SGLT2 inhibition in congestive heart failure
SGLT2 抑制对充血性心力衰竭有益作用的新靶点机制(肾神经)
- 批准号:
10472675 - 财政年份:2021
- 资助金额:
$ 9.96万 - 项目类别:
Novel target mechanism (renal nerves) for the beneficial actions of SGLT2 inhibition in congestive heart failure
SGLT2 抑制对充血性心力衰竭有益作用的新靶点机制(肾神经)
- 批准号:
10275320 - 财政年份:2021
- 资助金额:
$ 9.96万 - 项目类别:
I-Corps: Machine Learning based Clinical Decision Support Tool to Predict 30-day Hospital Readmissions for Congestive Heart Failure Patients
I-Corps:基于机器学习的临床决策支持工具,可预测充血性心力衰竭患者 30 天再入院情况
- 批准号:
2039546 - 财政年份:2020
- 资助金额:
$ 9.96万 - 项目类别:
Standard Grant
Development of therapeutic strategy against congestive heart failure by food ingredients.
通过食品成分开发针对充血性心力衰竭的治疗策略。
- 批准号:
20K05918 - 财政年份:2020
- 资助金额:
$ 9.96万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Stress and Congestive Heart Failure: A mechanistic clinical trial
压力和充血性心力衰竭:机械临床试验
- 批准号:
10657561 - 财政年份:2020
- 资助金额:
$ 9.96万 - 项目类别:
Stress and Congestive Heart Failure: A mechanistic clinical trial
压力和充血性心力衰竭:机械临床试验
- 批准号:
10200143 - 财政年份:2020
- 资助金额:
$ 9.96万 - 项目类别:
Stress and Congestive Heart Failure: A mechanistic clinical trial
压力和充血性心力衰竭:机械临床试验
- 批准号:
10452504 - 财政年份:2020
- 资助金额:
$ 9.96万 - 项目类别: